Pharmacokinetic
5
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
CT
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
2 programs2
LanifibranorPhase 11 trial
TQ-A3326Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chia Tai TianQing Pharmaceutical GroupLanifibranor
Novo NordiskINV-101
Gesynta PharmaFormulation A GS-248
Chia Tai TianQing Pharmaceutical GroupTQ-A3326
Bausch Healthrifaximin
Clinical Trials (5)
Total enrollment: 40 patients across 5 trials
A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
Start: Oct 2023Est. completion: Dec 2023
Phase 1Completed
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
Start: Sep 2020Est. completion: May 202140 patients
Phase 1Completed
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
Start: Mar 2020Est. completion: May 2020
Phase 1Completed
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
Start: Nov 2018Est. completion: Sep 2019
Phase 1Unknown
Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
Start: Sep 2008Est. completion: Nov 2008
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space